Crossmark

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Crossref DOI link: https://doi.org/10.1038/leu.2014.232

Published Online: 2014-07-31

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heuck, C J

Qu, P

van Rhee, F

Waheed, S

Usmani, S Z

Epstein, J

Zhang, Q

Edmondson, R

Hoering, A

Crowley, J

Barlogie, B
License Information

Text and Data Mining valid from 2014-07-31
More Information

Article History

First Online: 31 July 2014

Competing interests

: BB has received research funding from Celgene and Millennium, is a consultant to Celgene and Millennium, and is a co-inventor on patents and patent applications related to use of GEP in cancer medicine that have been licensed to Myeloma Health, LLC. SZU is a consultant to Celgene, Millennium and Onyx. He has received research funding from Onyx and Celgene, and speaking honoraria from Celgene. The remaining authors declare no conflict of interest.